Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amosartan plus L (Primary)
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms HM_APOLLO
  • Sponsors Hanmi Pharmaceutical

    • Most Recent Events

    • 23 Dec 2024 According to a Hanmi Pharmaceutical media release, announced on the 23rd that it has applied for domestic approval for 'HCP1803', the world's first 1/3 low-dose hypertension triple-drug combination drug in phase 3 clinical trials, under the name 'Amosartan Plus L Tablet'.
    • 21 Jun 2024 Results presented in a Hanmi Pharmaceutical Media Release.
    • 21 Jun 2024 According to a Hanmi Pharmaceutical media release, results from this study were presented at the European Society of Hypertension (ESH) annual conference held in Berlin, Germany from May 31 to June 4.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top